Pathways of tumor development and progression in drug-induced nonmelanoma skin cancer: A new hope or the next great confusion?

Wiener Medizinische Wochenschrift

Volumn 164, Issue 13-14, 2014, Pages 286-295

  Tchernev, Georgi ^a   Wollina, Uwe ^b  

^a UNIVERSITY OF SOFIA   (Bulgaria)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Apoptosis; ASC TMS1; Bax; NF kB; NMSC; p53; SCC; UVB

Indexed keywords

ADALIMUMAB; ADAPTOR PROTEIN; CALCINEURIN INHIBITOR; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INFLIXIMAB; METHOTREXATE; PROTEIN ASC; PROTEIN BAK; PROTEIN BAX; PROTEIN P53; PROTEIN TMS1; PSORALEN; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; CYTOSKELETON PROTEIN; PYCARD PROTEIN, HUMAN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CLINICAL FEATURE; DRUG INDUCED CANCER; GENOME; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NON MELANOMA SKIN CANCER; NONHUMAN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ANIMAL; CELL TRANSFORMATION; CHEMICALLY INDUCED; DISEASE COURSE; DRUG EFFECTS; EXPERIMENTAL MELANOMA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN; SKIN TUMOR;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; INFLAMMASOMES; MELANOMA, EXPERIMENTAL; SKIN; SKIN NEOPLASMS;

EID: 84906937799     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-014-0271-3     Document Type: Review

References (74)

1. Nindl I, Rösl F. Molecular pathogenesis of squamous cell carcinoma. The SCOPE Collaborative Group, editor. Skin cancer after organ transplantation. Cancer Treatment and Research 146. Springer; 2009. doi:10.1007/978-0-387-78574- 5-18
2. Nindl I, Rösl F. Molecular concepts of virus infections causing skin cancer in organ transplant recipients. Am J Transplant. 2008;8:2199-204.
3. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma-a role for antiapoptotic signalling pathways. Am J Dermatopathol. 2014. Epub ahead of print.
4. Tchernev G, Nenoff P. Dissecting the pathways of tumor escape - question of life and death? An Bras Dermatol. 2010;85:248-59.
5. Dupuy A, Valton J, Leduc S, Armier J, Galetto R, Gouble A, Lebuhotel C, Stary A, Pâques A, Duchateau P, Sarasin A, Daboussi F. Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALENTM. PLoS One. 2013;8:e78678.
6. Tchernev G. Apoptotic pathways, cell cycle regulation and cancer progression: review. Turkiye Klinikleri J Med Sci. 2009;29:952-8.
7. Iftner T, Elbel M, Schopp B, et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J. 2002;21:4741-8. (Pubitemid 34984361)
8. Purdije KJ, Pennington J, Proby CM, et al. The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J. 1999;18:5359-69. (Pubitemid 29465585)
9. Tchernev G, Orfanos CE. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl/2 related proteins Bax and Bak in cutaneous melanoma is associated with worse patients prognosis: preliminary findings. J Cutan Pathol. 2007;34:247-56. (Pubitemid 46239314)
10. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267:1445-9.
11. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem. 2009;284:34553-60.
12. Tchernev G, Geilen CC, Zouboulis CC, Orfanos CE. p53-role in regulation in cell cycle and apoptosis in carcinomas and malignant melanoma. Curr Med (Bulgarian). 2005;36:47-54.
13. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-8. (Pubitemid 28406815)
14. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-56. (Pubitemid 37328916)
15. Kotzev A, Tchernev G, Tchernev K. Carcinogenesis. Curr Med (Bulgarian). 2006;57:51-62.
16. Ziegler A, Johnson AS, Leffel DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372:773-6.
17. Ananthaswany HN, Pierceall WE. Molecular alterations in human skin tumors. Prog Clin Biol Res. 1992;376:61-84.
18. Popp S, Waltering S, Herbst C, et al. UVB-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer. 2002;99:352-60. (Pubitemid 34495849)
19. Boukamp P. Nonmelanoma skin cancer: what drives the tumor development and progression? Carcinogenesis. 2005;26:1657-67. (Pubitemid 41487981)
20. Alam N, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975-83. (Pubitemid 32240317)
21. Pierceall WE, Goldberg LH, Tainsky MA, et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog. 1991;4:196-202.
22. Corominas M, Kamino H, Leon J, et al. Oncogene activation in human benign tumors of the skin (keratoakanthomas): is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci U S A. 1989;86:6372-6. (Pubitemid 19210654)
23. Spencer JM, Kahn SM, Jiang W, et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol. 1995;131:796-800.
24. Omran OM, Ata HS. Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer. Environ Toxicol. 2012;27:433-44.
25. Yoldas B, Ozer C, Ozen O, Canpolat T, Dogan I, Griffith TH, Sanlioglu S, Ozluoglu LN. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck. 2011;33:1278-84.
26. Morales-Lara MJ, CanÈte JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, Garcia-Simón MS, Conesa-Zamora P. Effects of polymorphisms in TRAILR1 and TRAILR1A on the responce to anti TNF therapies with rheumatoid and psoriatic arthritis. Joint Bone Spine. 2012;79:591-6.
27. Sisto M, D'Amore M, Caprio S, Mitolo V, Scagliusi P, Lisi S. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands. Ann N Y Acad Sci. 2009;1171:407-14.
28. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8. (Pubitemid 35363648)
29. Burnet FM. Cancer-a biological approach: I. The processes of control. II. The significance of somatic mutation. BMJ. 1957;1:779-86.
30. Kim R, Emi M, Tanabe K. Cancer immunoediting from immunsurveillance to immune escape. J Immunol. 2007;121:1-14. (Pubitemid 46537674)
31. Dunn GP, Old LJ, Schreiber RD. The three ES of cancer immunoediting. Ann Rev Immunol. 2004;22:329-60. (Pubitemid 38680426)
32. Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels JP, Prenen H, Masson P, Louis E, De Keyser F. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer. 2013;12:98.
33. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kB as the matchmaker. Nat Immunol. 2011;12:715-23.
34. Barne PJ, Karin M. Nuclear factor kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;12:1066-71. (Pubitemid 27163860)
35. Hayden MS, Ghosh S. NF-kB, the first quarter century: remarkable progress and outstanding questions. Genes Dev. 2012;12:203-34.
36. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlquist S, Saxne T, Klareskog L, Feltenius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis. 2005;12:1414-20. (Pubitemid 41623850)
37. Karin M, Cao Y, Greten FR, Li Z-W. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;12:301-10. (Pubitemid 37328783)
38. Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Epigenetic regulation of ASC/TSM1 expression: potential role in apoptosis and inflammasome function. Cell Mol Life Sci. 2013. Epub ahead of print.
39. Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer. 2008;15:11-25. (Pubitemid 351449724)
40. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605-21. (Pubitemid 44666739)
41. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell. 2010;140:883-99.
42. Masumoto J, Taniguchi S, Ayukawa K, Sarvotham H, Kishino T, Niikawa N, Hidaka E, Katsuyama T, Higuchi T, Sagara J. ASC, a novel 22-kDa, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem. 1999;274:33835-8. (Pubitemid 129511704)
43. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target if methylation induced gene silencing in human breast cancers. Cancer Res. 2000;60:6236-42.
44. Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, Tonk V, Padar A, Takakashi T, Roth JA, Euhus DM, Minna JD, Cazdar AF. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int J Cancer. 2003;106:198-204. (Pubitemid 36835171)
45. Guan X, Sagara J, Yokoyama T, Koganehira Y, Oguchi M, Saida T, Taniguchi S. ASC/TSM1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer. 2003;107:202-8. (Pubitemid 37152898)
46. Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS. Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate. 2006;66:687-95.
47. Das PM, Ramachandran K, Vanwert J, Ferdinand L, Copisetty G, Reis IM, Singal R. Methylation-mediated silencing of ASC/TSM1 gene in prostate cancer. Mol Cancer. 2006;5:28.
48. Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM. Aberrant methylation and downregulation of ASC/TSM1 in human glioblastoma. Am J Pathol. 2004;165:1151-61. (Pubitemid 39297722)
49. Martinez R, Schakert G, Esteller M. Hypermethylation of the proapoptotic gene TSM1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol. 2007;82:133-9. (Pubitemid 46431855)
50. Grau E, Martinez F, Orellana C, Canete A, Yanez Y, Oltra S, Noguera R, Hernandez M, Bermudez JD, Castel V. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog. 2011;50:153-62.
51. Levine JJ, Stimson-Crider KM, Vertino PM. Effects of methylation on expression of TMS1/ASC in human breast cancer cells. Oncogene. 2003;22:3475-88. (Pubitemid 36713746)
52. Zhang C, Li H, Zhou G, Zhang Q, Zhang T, Li J, Liew CT, Yin D. Transcriptional silencing of the TMS1/ASC tumor suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J Pathol. 2007;212:134-42. (Pubitemid 46852091)
53. Zhang C, Bai J, Ren S, Wang R, Zhang L, Zuo Y. Sodium butyrate restores ASC expression and induces apoptosis in LS174T cells. Int J Mol Med. 2012;30:1431-7.
54. Ohtsuka T, Ryu H, Minamishima YA, Macip S, Sagara J, Nakayama KI, Aaronson SA, Lee SW. ASC is a Bax adaptor and regulates the p-53/Bax mitochnodrial apoptosis pathway. Nat Cell Biol. 2004;6:121-8. (Pubitemid 38425711)
55. Hasegawa M, Kawase K, Inohara N, Imamura R, Yeh WC, Kinoshita T, Suda T. Mechanism of ASC-mediated apoptosis: bid dependent apoptosis in type II cells. Oncogene. 2007;26:1748-56. (Pubitemid 46426195)
56. Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta. 2011;1813:558-63.
57. Motani K, Kawase K, Imamura R, Kinoshita T, Kushiyama H, Suda T. Activation of ASC induces apoptosis and necrosis, depending on the cell type, and causes tumor eradication. Cancer Sci. 2010;101:1822-7.
58. Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A. 2012;109:18384-9.
59. Ananiev J, Tchernev G. HPV-associated verrucous carcinoma of the perianal region-complete remission after surgical excision and postoperative monochemotherapy with methotrexat. Akush Ginekol (Sofiia). 2012;51:54-7.
60. Sakai T, Tamura S, Miyoshi T, Nesumi N, Nagai K, Oshima K. Development of myeloid sarcoma after long-term methotrexate use for rheumatoid arthritis. Int J Hematol. 2014. Epub ahead of print.
61. Saburi M, Itani K, Nagamatsu K, Miyazaki Y, Otsuka E, Urabe S, Saburi Y. Successful treatment with high-dose methotrexate/cytarabine regimen in a patient in SMILE regimen-resistant extranodal natural killer/T-cell lymphoma. Rinsho Ketsueki. 2014;55:120-4.
62. Galbiatti AL, Caldas HC, Padovani JA Jr, Pavarino EC, Goloni-Bertollo EM. Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy. Exp Oncol. 2012;34:367-9.
63. Liang XH, He YW, Tang YL, Wu JL, Cao XP, Xiao GZ, Mao ZY. Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases. J Craniomaxillofac Surg. 2010;38:260-5.
64. Sakoda T, Saitoh Y, Seno S, Ikeda H, Dake Y, Enomoto T, Kawano A, Kitano H. Combined MTX.5-FU.CDGP for the treatment of head and neck cancer. Gan To Kagaku Ryoho. 2003;30:641-5.
65. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol. 2006;7:255-60. (Pubitemid 44018818)
66. Mrass P, Rendl M, Mildner M, Gruber F, Lengauer B, Ballaun C, Eckhart L, Tschachler E. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res. 2004;64:6542-8. (Pubitemid 39297912)
67. Xiaofang L, Kun T, Shaoping Y, Zaiqiu W, Hailong S. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma. World J Surg Oncol. 2012;10:5.
68. Tchernev G, Orfanos CE. Malignant melanoma-apoptosis and melanoma. Curr Med (Bulgarian). 2005;56:56-61.
69. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12:1146-56.
70. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010;28:88-92.
71. Wimmer CD, Angele MK, Schwarz B, Pratschke S, Rentsch M, Khandoga A, Guba M, Jauch KW, Bruns C, Graeb C. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int. 2013;26:999-1006.
72. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835-42.
73. Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014;15:37-43.
74. Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Risk of malignancy including nonmelanoma skin cancers with antitumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol. 2012;30:756-64.